ClinicalTrials.gg
RecruitingNCT05111015TRAC-AFUpdated Jun 29, 2026

Tracking Results of Ablations to Combat AF Registry Generation 2

An observational study in Atrial Fibrillation, sponsored by AtriCure, Inc.. Recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by AtriCure, Inc. · Observational

How we know

From the registry’s dates

  • Started Mar 2024; still recruiting 2 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Other
Enrollment
10,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Atrial Fibrillation by AtriCure, Inc. — 2 open to participants now, 4 under way, none of them phase 3. Atrial Fibrillation · AtriCure, Inc..

Started
2024
the only one that year
Observational
2 of 27
1 open now
Registered
26th of 27
by date

Among the 27 studies in Atrial Fibrillation by AtriCure, Inc., this one is the only one that started in 2024, is one of 2 observational ones, and was the 26th registered.

Atrial Fibrillation

4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

2 of the 27 studies in Atrial Fibrillation by AtriCure, Inc. are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Atrial Fibrillation by AtriCure, Inc., or all of them as a file.
02

Study summary

The primary objective of the TRAC-AF Registry is to capture real-world safety and effectiveness data on AtriCure devices used to conduct open concomitant and/or hybrid ablation, and management of the LAA concomitant to a cardiac ablation.

Read the detailed description

Up to 10,000 patients at up to 250 sites. Participating regions may include US, Canada, Europe, Asia Pacific and others to be determined. Registry participating sites will enroll patients that meet all inclusion criteria and no exclusion criteria without preselection or bias. Each patient will be followed for a period of up to ten (10) years after their procedure according to the standard practice at the enrolling center. There will be no additional visits, nor procedures, for subjects who participate in the registry.

03

Conditions studied

  • Atrial Fibrillation

Browse trials for

Keywords

  • Atrial Fibrillation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The TRAC-AF registry eligibility is open to sites and physicians performing open concomitant or hybrid ablation therapy procedures as treatments for patients diagnosed with paroxysmal, persistent or long-standing persistent atrial fibrillation using at least one of AtriCure's ablation devices. Subjects must have been scheduled to undergo or have undergone the cardiac ablation treatment and must meet all eligibility criteria in order for their treatment and results to be considered for this registry.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient has been scheduled by physician(s) to undergo or has undergone cardiac ablation procedure(s)
  2. Patient is willing to provide
  3. Patient whose age is 18 years or above, or of legal age to give informed consent specific to state and national law

Exclusion criteria

Exclusion Criteria:

1. Other medical, social, or psychological conditions that in the opinion of the Investigator precludes the subject from appropriate consent or adherence to the protocol.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Other
Enrollment
10,000 participants (estimated)
Target follow-up
10 Years
Patient registry
Yes

Interventions

  • DeviceOpen Concomitant Surgical Ablation Procedures

    AtriCure's Open Concomitant Surgical Ablation Devices used for the management of Atrial Fibrillation.

  • DeviceHybrid (Convergent) Ablation Procedures

    AtriCure's Hybrid (Convergent) Ablation Devices used for the management of Atrial Fibrillation.

  • DeviceAtriCure Hybrid Totally Thoracoscopic Ablation Procedures

    AtriCure's Hybrid Totally Thoracoscopic Surgical Ablation Devices used for the management of Atrial Fibrillation.

  • DeviceAtriCure LAA Exclusion Procedures

    AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the management of Atrial Fibrillation.

06

What researchers measure

Primary outcomes

  1. Patient's AF burden 6-month after receiving the ablation procedure

    Collect patient data on Atrial Fibrillation burden after the ablation procedure as documented by long term event monitoring or identified during the exam after a six-month recovery period.

    Time frame: 6 months

  2. Adverse events of the ablation procedure as atrial fibrillation management

    Collect data on adverse events occurred during and post operation to assess the safety of the ablation procedure.

    Time frame: 1 year

Other outcomes

  1. Medications

    On/Off AAD or Anticoagulant post procedure

    Time frame: 12 months

07

Study locations

29 of 29 sites recruiting
08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2024 (actual). Primary completion is estimated for Jan 2040, 190 months after the start.

Of 148 industry-sponsored observational studies under Atrial Fibrillation, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 42. This study's planned 190 months is above that.

Counting every sponsor, half of 700 studies reached it within 38 months; a quarter within 22 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2021
First posted
Nov 8, 2021
StartActual
Mar 11, 2024
Primary completionEst.
Jan 2040
CompletionEst.
Jan 2040
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05111015
Lead sponsor
AtriCure, Inc.
Responsible party
Sponsor
First posted
Nov 8, 2021
Start date
Mar 11, 2024
Primary completion
Jan 2040 (estimated)
Completion
Jan 2040 (estimated)
Last update
Jun 29, 2026

Study contacts

Jarrod Goodarz, BA
Contact
jgoodarz@atricure.com
609-331-6621
Joey Stimler, DPT
Contact
jstimler@atricure.com
513-926-3875

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion